Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.

Giulia DaghiaTatjana ZabelinaGaby ZeckUte-Marie von PeinMaximilian ChristopeitChristine WolschkeFrancis AyukNicolaus Kröger

Published in: European journal of haematology (2019)

Reduced intensity conditioning regimen followed by ASCT in older patients with myelofibrosis is a curative treatment option. Outcome is more favorable in patients with no or minimal comorbidities.

Keyphrases

stem cell transplantation
high dose
end stage renal disease
prognostic factors
ejection fraction
newly diagnosed
chronic kidney disease
bone marrow
physical activity
rectal cancer
low dose
patient reported outcomes
middle aged